Research / SOFI / Fundamental state Inspectable configuration
State dimensions Filing 0001818874-24-000026 Bank
Sequential deposit growth RAW Current state valid · history insufficient
Evidence method Sequential · gp.financial.deposits
18.82% · CORE · NOT_ENOUGH_HISTORY
Interest-expense growth RAW Current state valid · history insufficient
Evidence method Yoy · gp.financial.interest_expense
317.03% · CORE · NOT_ENOUGH_HISTORY
Cash and equivalents 100th Own-history percentile · N=13
Evidence method Level · gp.fundamentals.cash
$3.1B · CORE · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 17 states Self-history eligible
Jun 30, 2022 0/3 normalized Level 3 Sep 30, 2022 1/3 normalized Level 3 Dec 31, 2022 1/3 normalized Level 3 Mar 31, 2023 1/3 normalized Level 3 Jun 30, 2023 1/3 normalized Level 3 Sep 30, 2023 1/3 normalized Level 3 Dec 31, 2023 1/3 normalized Level 3 Mar 31, 2024 1/3 normalized Level 3 Jun 30, 2024 2/3 normalized Level 3 Sep 30, 2024 2/3 normalized Level 3 Dec 31, 2024 2/3 normalized Level 3 Mar 31, 2025 2/4 normalized Level 3 Jun 30, 2025 2/4 normalized Level 3 Sep 30, 2025 2/4 normalized Level 3 Dec 31, 2025 2/4 normalized Level 3 Mar 31, 2026 2/4 normalized Level 3 Jun 30, 2026 3/4 normalized Level 4 Period transition
What moved in the state? Deposit Growth Decreased
Previous 23.01%
Current 18.82%
Delta -4.20% Funding Cost Growth Decreased
Previous 445.69%
Current 317.03%
Delta -128.66% Liquidity Increased
Previous $2.8B
Current $3.1B
Delta $271.1M Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.